Merck – Page 2 – media

Experimental Merck vaccine gears up to fight Congo Ebola outbreak

As the Democratic Republic of Congo deals with a rising death toll owing to the latest outbreak of Ebola, health officials are moving fast to counter the fatal effects of the deadly virus. Plans are afoot to implement the experimental vaccine developed by Merck & Co to confront the overwhelming challenges posed by the virus.
- Source: Ddu
- 730
- May 15, 2018
Ebola Merck New Approvals vaccines
Boosted by China launch, Merck’s Gardasil turns in a big first-quarter performance

Merck generated more than $1.5 billion in first-quarter vaccine sales. (Merck)
- Source: fiercepharma
- 592
- May 9, 2018
Gardasil HPV vaccine Merck
Moderna and Merck Expand mRNA Cancer Vaccines Collaboration

Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna
- Source: investors.merck
- 530
- May 7, 2018
Merck mRNA cancer vaccines
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer

First Filing Acceptance for an Anti-PD-1 Therapy in Cervical Cancer
- Source: investors.merck
- 641
- May 2, 2018
cervical cancer FDA keytruda Merck
Merck KGaA, not Pfizer, lands consumer health deal with P&G worth $4.2B

Merck KGaA will hand P&G a consumer business that has grown 6% over the past two years. (Merck KGaA) Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.
- Source: fiercepharma
- 3,315
- April 23, 2018
Company Insight consumer business Merck
KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells

Based on the recommendation of the DMC, the trial will continue to evaluate progression-free survival (PFS), which is a secondary endpoint. Results from KEYNOTE-042 will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.
- Source: finance.yahoo
- 690
- April 10, 2018
Clinical Trials keytruda Merck NSCLC
Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.
- Source: Merck
- 525
- February 19, 2018
Company Insight Merck
Shooting for a new standard on osteoarthritis, Merck KGaA outlines promising data for a potential game-changer

Merck KGaA’s pharma group is taking one more step in a long journey toward rehabbing its rep in the R&D field this weekend. Company execs turned up at the ACR scientific conference in San Diego to roll out a promising look at some key Phase II osteoarthritis data — which comes with a critical caveat.
- Source: Endpts
- 651
- November 13, 2017
Merck osteoarthritis R&D sprifermin
Merck subsidiary StayWell acquires app maker MedHelp for undisclosed sum

To expedite its push into mobile health, Yardley, Pennsylvania-based StayWell announced today that it has acquired the mobile health portion of Silicon Valley-based MedHelp, which includes several consumer-facing mobile health apps.
- Source: mobihealthnews
- 502
- November 6, 2017
Company Insight health apps MedHelp Merck
Samsung Biologics reinforces biologic manufacturing and development partnership with MSD

Samsung Biologics has announced it has expanded its strategic alliance with MSD, or Merck as it is known in the US and Canada, with the signing of a memorandum of understanding. The relationship has come into force to streamline process development and clinical material production for small biotech start-ups focusing on novel drugs.
- Source: pharmafile
- 434
- November 1, 2017
Merck Samsung Biologics

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.